|
VaxGen has tried to save the world from a killer, but first it will have to save itself. After its HIV vaccine failed in late-stage clinical trials, the company shifted focus to developing vaccines for bioterrorism threats. It was the first big winner of the Project BioShield Act of 2004, winning a contract worth some $880 million to produce an anthrax vaccine for the US government's civilian stockpile. The Department of Health and Human Services terminated the contract in 2007, however, after the troubled program failed to begin a clinical trial by a set deadline. In response, VaxGen slashed its workforce and began seeking strategic alternatives. It sold its anthrax program to Emergent BioSolutions in 2008.
|
| | | Contact Information | |
Address: |
349 Oyster Point Blvd., Ste. 10
South San Francisco, CA 94080
| | Phone: | 650-624-1000 | | Fax: | 650-624-4785 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.30 M | | Revenue Growth (1 yr): | (-94.20%) | | Employees (2008): | 3 | | Employee Growth (1 yr): | (-98.60%) |
|
|
Key People
| | • |
President, CEO, Principal Financial Officer, and Director:
James P. (Jim) Panek
|
|
|
